Education
About Us
Working with TipRanks
Follow Us
Lyell Immunopharma, Inc. (LYEL)
:LYEL
Total Valuation
Lyell Immunopharma has a market cap or net worth of $210.55M. The enterprise value is -$99.42M.
Market Cap$210.55M
Enterprise Value-$99.42M
Share Statistics
Lyell Immunopharma has 19,211,203 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding19,211,203
Owned by Insiders15.94%
Owned by Institutions19.78%
Financial Efficiency
Lyell Immunopharma’s return on equity (ROE) is -0.90 and return on invested capital (ROIC) is -79.19%.
Return on Equity (ROE)-0.90
Return on Assets (ROA)-0.70
Return on Invested Capital (ROIC)-79.19%
Return on Capital Employed (ROCE)-0.82
Revenue Per Employee203.33
Profits Per Employee-1.14M
Employee Count300
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Lyell Immunopharma is ―. Lyell Immunopharma’s PEG ratio is ―.
PE Ratio―
PS Ratio―
PB Ratio―
Price to Fair Value8.74
Price to FCF―
Price to Operating Cash Flow-0.91
PEG Ratio―
Income Statement
In the last 12 months, Lyell Immunopharma had revenue of 61.00K and earned -342.99M in profits. Earnings per share was -1.31.
Revenue61.00K
Gross Profit61.00K
Operating Income-358.75M
Pretax Income-342.99M
Net Income-342.99M
EBITDA-200.64M
Earnings Per Share (EPS)-1.31
Cash Flow
In the last 12 months, operating cash flow was -171.48M and capital expenditures -517.00K, giving a free cash flow of -172.00M billion.
Operating Cash Flow-171.48M
Free Cash Flow-172.00M
Free Cash Flow per Share-8.95
Dividends & Yields
Lyell Immunopharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.00
52-Week Price Change-61.37%
50-Day Moving Average10.37
200-Day Moving Average11.95
Relative Strength Index (RSI)55.92
Average Volume (3m)57.10K
Important Dates
Lyell Immunopharma upcoming earnings date is Nov 11, 2025, After Close (Confirmed).
Last Earnings DateAug 12, 2025
Next Earnings DateNov 11, 2025
Ex-Dividend Date―
Financial Position
Lyell Immunopharma as a current ratio of 7.06, with Debt / Equity ratio of 15.59%
Current Ratio7.06
Quick Ratio7.06
Debt to Market Cap<0.01
Net Debt to EBITDA0.23
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Lyell Immunopharma has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Lyell Immunopharma EV to EBITDA ratio is -16.45, with an EV/FCF ratio of -20.26.
EV to Sales54.10K
EV to EBITDA-16.45
EV to Free Cash Flow-20.26
EV to Operating Cash Flow-20.32
Balance Sheet
Lyell Immunopharma has $276.79M in cash and marketable securities with $46.60M in debt, giving a net cash position of -$230.19M billion.
Cash & Marketable Securities$276.79M
Total Debt$46.60M
Net Cash-$230.19M
Net Cash Per Share-$11.98
Tangible Book Value Per Share$1.46
Margins
Gross margin is 86.67%, with operating margin of -588122.95%, and net profit margin of -562285.25%.
Gross Margin86.67%
Operating Margin-588122.95%
Pretax Margin-562285.25%
Net Profit Margin-562285.25%
EBITDA Margin-328922.95%
EBIT Margin-361104.92%
Analyst Forecast
The average price target for Lyell Immunopharma is $11.00, which is 11.43% higher than the current price. The consensus rating is Moderate Sell
Price Target$11.00
Price Target Upside-2.48% Downside
Analyst ConsensusModerate Sell
Analyst Count3
Revenue Growth Forecast11.11%
EPS Growth Forecast-46.50%